LCH-III Treatment Protocol of the Third International Study for LANGERHANS CELL HISTIOCYTOSIS - LCH-III

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002388-15-IT

Enrollment

500

Registered

2012-03-05

Start date

2005-03-10

Completion date

Unknown

Last updated

2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhans cell Histiocytosis MedDRA version: 14.1 Level: HLT Classification code 10020118 Term: Histiocytoses System Organ Class: 10005329 - Blood and lymphatic system disorders

Interventions

Pharmaceutical Form: Solution for injection INN or Proposed INN: Vinblastine CAS Number: 143-67-9 Concentration unit: mg milligram(s) Concentration number: 10- Pharmaceutical Form: Tablet INN or Prop

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the efficacy of intesification of therapy with MTX in multisystem LCH; to evaluate the efficacy of extended duration of therapy for non-localized LCH;Secondary Objective: Reduction of the numebr of sequelae;Primary end point(s): Survival	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026